1. Home
  2. NVRI vs CRVS Comparison

NVRI vs CRVS Comparison

Compare NVRI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$19.75

Market Cap

1.5B

Sector

Miscellaneous

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.41

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
CRVS
Founded
1853
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
NVRI
CRVS
Price
$19.75
$14.41
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$28.20
AVG Volume (30 Days)
1.3M
1.1M
Earning Date
04-30-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
$2,240,358,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.72
$2.54
52 Week High
$19.95
$26.95

Technical Indicators

Market Signals
Indicator
NVRI
CRVS
Relative Strength Index (RSI) 68.40 44.97
Support Level $17.64 $12.95
Resistance Level N/A $18.73
Average True Range (ATR) 0.42 1.01
MACD 0.18 0.03
Stochastic Oscillator 89.67 42.98

Price Performance

Historical Comparison
NVRI
CRVS

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: